Asprosin antibody
Quick Overview for Asprosin antibody (ABIN6253476)
Target
Reactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Purpose
- anti-Asprosin, mAb (Birdy-1)
-
Characteristics
- Monoclonal Antibody. Recognizes human & mouse asprosin and human & mouse fibrillin-1 (by homology). Isotype: Mouse IgG1. Clone: Birdy-1. Application: ELISA, WB. Liquid. In PBS containing 10 % glycerol and 0.02 % sodium azide. Asprosin is a new fasting-induced protein hormone that targets the liver to increase plasma glucose levels. Asprosin is the C-terminal cleavage product of the protein fibrillin-1. Asprosin is secreted from white adipose tissue and increases hepatic glucose production by using cAMP as a second messenger, leading to activation of protein kinase A in the liver. Reduction of asprosin levels protect against metabolic syndrome-associated hyperinsulinism.
-
Purity
- >95 % (SDS-PAGE)
-
Immunogen
- Recombinant human asprosin.
-
Isotype
- IgG1
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- Lot specific
-
Buffer
- Liquid. In PBS containing 10 % glycerol and 0.02 % sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- After opening, prepare aliquots and store at -20 °C. Avoid freeze/thaw cycles.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
-
Short Term Storage: +4°C
Long Term Storage: -20°C
Use & Stability: Stable for at least 1 year after receipt when stored at -20°C.
-
-
- Asprosin
-
Background
-
Alternate Names/Synonyms: Fibrillin-1 C-terminal Cleavage Product, FBN1 C Terminal Cleavage Product
Product Description: Asprosin is a new fasting-induced protein hormone that targets the liver to increase plasma glucose levels. Asprosin is the C-terminal cleavage product of the protein fibrillin-1. Asprosin is secreted from white adipose tissue and increases hepatic glucose production by using cAMP as a second messenger, leading to activation of protein kinase A in the liver. Reduction of asprosin levels protect against metabolic syndrome-associated hyperinsulinism.
Target
-